These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28376163)

  • 1. Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
    Garrido-Castro AC; Winer EP
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376163
    [No Abstract]   [Full Text] [Related]  

  • 2. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
    Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
    PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
    Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
    Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
    Ongaro E; Gerratana L; Cinausero M; Pelizzari G; Poletto E; Giangreco M; Andreetta C; Pizzolitto S; Di Loreto C; Minisini AM; Mansutti M; Russo S; Fasola G; Puglisi F
    Future Oncol; 2018 Apr; 14(9):849-859. PubMed ID: 29527957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score.
    Bowles DW; Rabinovitch R; Borges V; Urquhart A; Singh M; Finlayson C; Elias A
    Oncology (Williston Park); 2007 Sep; 21(10):1212-7. PubMed ID: 17926799
    [No Abstract]   [Full Text] [Related]  

  • 13. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
    Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
    Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
    He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
    PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer.
    Sato K; Akimoto K
    Clin Breast Cancer; 2017 Jun; 17(3):e135-e142. PubMed ID: 27986439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly informative marker sets consisting of genes with low individual degree of differential expression.
    Galatenko VV; Shkurnikov MY; Samatov TR; Galatenko AV; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
    Sci Rep; 2015 Oct; 5():14967. PubMed ID: 26446398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.